You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOlsalazine
Accession NumberDB01250
TypeSmall Molecule
GroupsApproved
DescriptionOlsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine is a derivative of salicylic acid. Inactive by itself (it is a prodrug), it is converted by the bacteria in the colon to mesalamine. Mesalamine works as an anti-inflammatory agent in treating inflammatory diseases of the intestines.
Structure
Thumb
Synonyms
Dipentum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dipentumcapsule, gelatin coated250 mg/1oralMEDA Pharmaceuticals2015-05-15Not applicableUs
Dipentumcapsule, gelatin coated250 mg/1oralCarilion Materials Management1990-07-31Not applicableUs
Dipentumcapsule, gelatin coated250 mg/1oralAlaven Pharmaceutical LLC1990-07-31Not applicableUs
Dipentumcapsule250 mgoralAtnahs Pharma Uk Limited1995-12-31Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Olsalazine sodium
6054-98-4
Thumb
  • InChI Key: QQWFSVYVHLECFP-XBPUGJBTSA-L
  • Monoisotopic Mass: 346.017775348
  • Average Mass: 346.2027
DBSALT000191
Categories
UNIIULS5I8J03O
CAS number15722-48-2
WeightAverage: 302.239
Monoisotopic: 302.053886062
Chemical FormulaC14H10N2O6
InChI KeyInChIKey=QQBDLJCYGRGAKP-FOCLMDBBSA-N
InChI
InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+
IUPAC Name
5-[(E)-2-(3-carboxy-4-hydroxyphenyl)diazen-1-yl]-2-hydroxybenzoic acid
SMILES
OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(O)C(=C1)C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as azobenzenes. These are organonitrogen aromatic compounds that contain a central azo group, where each nitrogen atom is conjugated to a bezene ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzobenzenes
Sub ClassNot Available
Direct ParentAzobenzenes
Alternative Parents
Substituents
  • Azobenzene
  • Salicylic acid
  • Salicylic acid or derivatives
  • Hydroxybenzoic acid
  • Benzoic acid
  • Benzoic acid or derivatives
  • Benzoyl
  • Phenol
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Vinylogous acid
  • Azo compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of Inflammatory Bowel Disease and Ulcerative Colitis.
PharmacodynamicsOlsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine reduces the bowel inflammation, diarrhea (stool frequency), rectal bleeding, and abdominal pain. Like Balsalazide, Olsalazine is believed to deliver Mesalazine, or 5-aminosalicylic acid (5-ASA), past the small intestine, directly to the large intestine, which is that active site of disease in ulcerative colitis.
Mechanism of actionOrally administered olsalazine is converted to mesalamine which is thought to be the therapeutically active agent in the treatment of ulcerative colitis. The mechanism of action of mesalamine (and sulfasalazine) is unknown, but appears to be topical rather than systemic. Mucosal production of arachidonic acid (AA) metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes (LTs) and hydroxyelcosatetraenoic acids (HETEs) is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin (PG) production in the colon.
Related Articles
AbsorptionAfter oral administration, olsalazine, has limited systemic bioavailability. 98-99% of the dose is converted to mesalamine (5-ASA) in the colon, which is absorbed slowly resulting in very high local concentrations in the colon.
Volume of distributionNot Available
Protein bindingOlsalazine and olsalazine-S are more than 99% bound to plasma proteins. Mesalamine (5-ASA) is 74% bound to plasma proteins.
Metabolism

Most (98 to 99%) of an oral dose is rapidly converted into two molecules of 5-aminosalicylic acid (5-ASA) by colonic bacteria and the low prevailing redox potential found in this environment. The conversion of olsalazine to mesalamine in the colon is similar to that of sulfasalazine, which is converted into sulfapyridine and mesalamine. Approximately 0.1% of an oral dose of olsalazine is metabolized in the liver to olsalazine-O-sulfate (olsalazine-S)

SubstrateEnzymesProduct
Olsalazine
Not Available
Olsalazine-O-sulfateDetails
Route of eliminationApproximately 0.1% of an oral dose of olsalazine is metabolized in the liver to olsalazine-O-sulfate (olsalazine-S).The remaining 5-ASA is partially acetylated and is excreted in the feces.
Half lifeOlsalazine has an elimination half-life of 0.9 hours, however, olsalazine-S has a half-life of 7 days.
ClearanceNot Available
ToxicityMaximum single oral doses of 5g/kg in mice and rats and 2 g/kg in dogs were not lethal.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8502
Blood Brain Barrier+0.6279
Caco-2 permeable-0.6449
P-glycoprotein substrateNon-substrate0.7433
P-glycoprotein inhibitor INon-inhibitor0.8628
P-glycoprotein inhibitor IINon-inhibitor0.9525
Renal organic cation transporterNon-inhibitor0.8844
CYP450 2C9 substrateNon-substrate0.7774
CYP450 2D6 substrateNon-substrate0.8748
CYP450 3A4 substrateNon-substrate0.6636
CYP450 1A2 substrateNon-inhibitor0.8006
CYP450 2C9 inhibitorNon-inhibitor0.7804
CYP450 2D6 inhibitorNon-inhibitor0.9047
CYP450 2C19 inhibitorNon-inhibitor0.8638
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8912
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.5546
BiodegradationNot ready biodegradable0.8701
Rat acute toxicity1.4882 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9506
hERG inhibition (predictor II)Non-inhibitor0.9453
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral250 mg
Capsule, gelatin coatedoral250 mg/1
Prices
Unit descriptionCostUnit
Dipentum 250 mg capsule1.8USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting pointSodium salt decomposes at 240 °CNot Available
logP2.3Not Available
Caco2 permeability-6.96ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0781 mg/mLALOGPS
logP2.77ALOGPS
logP4.39ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)2.93ChemAxon
pKa (Strongest Basic)-0.019ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area139.78 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity78.85 m3·mol-1ChemAxon
Polarizability28.61 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesA07EC03
AHFS Codes
  • 56:36.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabOlsalazine may increase the anticoagulant activities of Abciximab.
AcebutololOlsalazine may decrease the antihypertensive activities of Acebutolol.
AceclofenacAceclofenac may increase the nephrotoxic activities of Olsalazine.
AceclofenacThe risk or severity of adverse effects can be increased when Olsalazine is combined with Aceclofenac.
AcenocoumarolOlsalazine may increase the anticoagulant activities of Acenocoumarol.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Olsalazine.
Acetylsalicylic acidAcetylsalicylic acid may increase the nephrotoxic activities of Olsalazine.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Acetylsalicylic acid.
AdapaleneAdapalene may increase the nephrotoxic activities of Olsalazine.
AdapaleneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Adapalene.
Alendronic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Alendronic acid.
AliskirenOlsalazine may decrease the antihypertensive activities of Aliskiren.
AlprenololOlsalazine may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Olsalazine.
AmikacinOlsalazine may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideOlsalazine may decrease the antihypertensive activities of Amiloride.
AncrodOlsalazine may increase the anticoagulant activities of Ancrod.
AntipyrineAntipyrine may increase the nephrotoxic activities of Olsalazine.
AntipyrineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Antipyrine.
Antithrombin III humanOlsalazine may increase the anticoagulant activities of Antithrombin III human.
ApixabanOlsalazine may increase the anticoagulant activities of Apixaban.
ApremilastApremilast may increase the nephrotoxic activities of Olsalazine.
ApremilastThe risk or severity of adverse effects can be increased when Olsalazine is combined with Apremilast.
ArdeparinOlsalazine may increase the anticoagulant activities of Ardeparin.
ArgatrobanOlsalazine may increase the anticoagulant activities of Argatroban.
ArotinololOlsalazine may decrease the antihypertensive activities of Arotinolol.
AtenololOlsalazine may decrease the antihypertensive activities of Atenolol.
AzapropazoneAzapropazone may increase the nephrotoxic activities of Olsalazine.
AzapropazoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Azapropazone.
AzathioprineThe metabolism of Azathioprine can be decreased when combined with Olsalazine.
AzelastineAzelastine may increase the nephrotoxic activities of Olsalazine.
AzelastineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Olsalazine.
BalsalazideBalsalazide may increase the nephrotoxic activities of Olsalazine.
BecaplerminOlsalazine may increase the anticoagulant activities of Becaplermin.
BefunololOlsalazine may decrease the antihypertensive activities of Befunolol.
BemiparinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Bemiparin.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Olsalazine.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Olsalazine.
BenoxaprofenBenoxaprofen may increase the nephrotoxic activities of Olsalazine.
BenoxaprofenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Benoxaprofen.
BetaxololOlsalazine may decrease the antihypertensive activities of Betaxolol.
BevantololOlsalazine may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Olsalazine.
BisoprololOlsalazine may decrease the antihypertensive activities of Bisoprolol.
BivalirudinOlsalazine may increase the anticoagulant activities of Bivalirudin.
BopindololOlsalazine may decrease the antihypertensive activities of Bopindolol.
BromfenacBromfenac may increase the nephrotoxic activities of Olsalazine.
BromfenacThe risk or severity of adverse effects can be increased when Olsalazine is combined with Bromfenac.
BufuralolOlsalazine may decrease the antihypertensive activities of Bufuralol.
BumetanideOlsalazine may decrease the diuretic activities of Bumetanide.
BupranololOlsalazine may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Olsalazine.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Olsalazine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Olsalazine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Olsalazine.
CarprofenCarprofen may increase the nephrotoxic activities of Olsalazine.
CarprofenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Carprofen.
CarteololOlsalazine may decrease the antihypertensive activities of Carteolol.
CarvedilolOlsalazine may decrease the antihypertensive activities of Carvedilol.
CastanospermineCastanospermine may increase the nephrotoxic activities of Olsalazine.
CastanospermineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Castanospermine.
CelecoxibCelecoxib may increase the nephrotoxic activities of Olsalazine.
CelecoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Celecoxib.
CeliprololOlsalazine may decrease the antihypertensive activities of Celiprolol.
CertoparinOlsalazine may increase the anticoagulant activities of Certoparin.
ChloroquineChloroquine may increase the nephrotoxic activities of Olsalazine.
ChloroquineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Chloroquine.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olsalazine.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Olsalazine.
CholestyramineCholestyramine can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Olsalazine.
Citric AcidOlsalazine may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Clodronate.
ClonixinClonixin may increase the nephrotoxic activities of Olsalazine.
ClonixinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Olsalazine.
ColesevelamColesevelam can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineOlsalazine may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneD-Limonene may increase the nephrotoxic activities of Olsalazine.
D-LimoneneThe risk or severity of adverse effects can be increased when Olsalazine is combined with D-Limonene.
Dabigatran etexilateOlsalazine may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinOlsalazine may increase the anticoagulant activities of Dalteparin.
DanaparoidOlsalazine may increase the anticoagulant activities of Danaparoid.
DaunorubicinOlsalazine may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Olsalazine is combined with Deferasirox.
DesirudinOlsalazine may increase the anticoagulant activities of Desirudin.
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Olsalazine.
DesmopressinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Olsalazine.
DextranOlsalazine may increase the anticoagulant activities of Dextran.
Dextran 40Olsalazine may increase the anticoagulant activities of Dextran 40.
Dextran 70Olsalazine may increase the anticoagulant activities of Dextran 70.
Dextran 75Olsalazine may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Olsalazine.
DicoumarolOlsalazine may increase the anticoagulant activities of Dicoumarol.
DiflunisalDiflunisal may increase the nephrotoxic activities of Olsalazine.
DiflunisalThe risk or severity of adverse effects can be increased when Olsalazine is combined with Diflunisal.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Olsalazine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Olsalazine.
DihydrostreptomycinOlsalazine may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Olsalazine.
DoxorubicinOlsalazine may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneOlsalazine may increase the hyperkalemic activities of Drospirenone.
DroxicamDroxicam may increase the nephrotoxic activities of Olsalazine.
DroxicamThe risk or severity of adverse effects can be increased when Olsalazine is combined with Droxicam.
Edetic AcidOlsalazine may increase the anticoagulant activities of Edetic Acid.
EdoxabanOlsalazine may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Olsalazine.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Olsalazine.
EnoxaparinOlsalazine may increase the anticoagulant activities of Enoxaparin.
EpirizoleEpirizole may increase the nephrotoxic activities of Olsalazine.
EpirizoleThe risk or severity of adverse effects can be increased when Olsalazine is combined with Epirizole.
EpirubicinOlsalazine may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneOlsalazine may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Olsalazine.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Olsalazine.
EsmololOlsalazine may decrease the antihypertensive activities of Esmolol.
Etacrynic acidOlsalazine may decrease the diuretic activities of Etacrynic acid.
EtanerceptEtanercept may increase the nephrotoxic activities of Olsalazine.
EtanerceptThe risk or severity of adverse effects can be increased when Olsalazine is combined with Etanercept.
Ethyl biscoumacetateOlsalazine may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Etidronic acid.
EtodolacEtodolac may increase the nephrotoxic activities of Olsalazine.
EtodolacThe risk or severity of adverse effects can be increased when Olsalazine is combined with Etodolac.
EtofenamateEtofenamate may increase the nephrotoxic activities of Olsalazine.
EtofenamateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Etofenamate.
EtoricoxibEtoricoxib may increase the nephrotoxic activities of Olsalazine.
EtoricoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Etoricoxib.
Evening primrose oilEvening primrose oil may increase the nephrotoxic activities of Olsalazine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Evening primrose oil.
exisulindexisulind may increase the nephrotoxic activities of Olsalazine.
exisulindThe risk or severity of adverse effects can be increased when Olsalazine is combined with exisulind.
FenbufenFenbufen may increase the nephrotoxic activities of Olsalazine.
FenbufenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fenbufen.
FenoprofenFenoprofen may increase the nephrotoxic activities of Olsalazine.
FenoprofenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fenoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Olsalazine.
FlunixinFlunixin may increase the nephrotoxic activities of Olsalazine.
FlunixinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Flunixin.
FlurbiprofenFlurbiprofen may increase the nephrotoxic activities of Olsalazine.
FlurbiprofenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Flurbiprofen.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Olsalazine.
Fondaparinux sodiumOlsalazine may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Olsalazine.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Olsalazine.
FramycetinOlsalazine may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideOlsalazine may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Olsalazine.
GentamicinOlsalazine may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Olsalazine is combined with Haloperidol.
HeparinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Heparin.
HirulogOlsalazine may increase the anticoagulant activities of Hirulog.
HMPL-004HMPL-004 may increase the nephrotoxic activities of Olsalazine.
HMPL-004The risk or severity of adverse effects can be increased when Olsalazine is combined with HMPL-004.
HydralazineOlsalazine may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Olsalazine.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Olsalazine.
Hygromycin BOlsalazine may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ibandronate.
IbuprofenIbuprofen may increase the nephrotoxic activities of Olsalazine.
IbuprofenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ibuprofen.
IbuproxamIbuproxam may increase the nephrotoxic activities of Olsalazine.
IbuproxamThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ibuproxam.
IcatibantIcatibant may increase the nephrotoxic activities of Olsalazine.
IcatibantThe risk or severity of adverse effects can be increased when Olsalazine is combined with Icatibant.
IdarubicinOlsalazine may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Olsalazine.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Olsalazine.
IndenololOlsalazine may decrease the antihypertensive activities of Indenolol.
IndomethacinIndomethacin may increase the nephrotoxic activities of Olsalazine.
IndomethacinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Indomethacin.
IndoprofenIndoprofen may increase the nephrotoxic activities of Olsalazine.
IndoprofenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Olsalazine.
IsoxicamIsoxicam may increase the nephrotoxic activities of Olsalazine.
IsoxicamThe risk or severity of adverse effects can be increased when Olsalazine is combined with Isoxicam.
KanamycinOlsalazine may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneKebuzone may increase the nephrotoxic activities of Olsalazine.
KebuzoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Kebuzone.
KetoprofenKetoprofen may increase the nephrotoxic activities of Olsalazine.
KetoprofenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Olsalazine.
LabetalolOlsalazine may decrease the antihypertensive activities of Labetalol.
LeflunomideLeflunomide may increase the nephrotoxic activities of Olsalazine.
LeflunomideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Leflunomide.
LepirudinOlsalazine may increase the anticoagulant activities of Lepirudin.
LevobunololOlsalazine may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Olsalazine.
LithiumThe serum concentration of Lithium can be increased when it is combined with Olsalazine.
LornoxicamLornoxicam may increase the nephrotoxic activities of Olsalazine.
LornoxicamThe risk or severity of adverse effects can be increased when Olsalazine is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Olsalazine.
LoxoprofenLoxoprofen may increase the nephrotoxic activities of Olsalazine.
LoxoprofenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Olsalazine.
LumiracoxibLumiracoxib may increase the nephrotoxic activities of Olsalazine.
LumiracoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Lumiracoxib.
Magnesium salicylateMagnesium salicylate may increase the nephrotoxic activities of Olsalazine.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Magnesium salicylate.
MasoprocolMasoprocol may increase the nephrotoxic activities of Olsalazine.
MasoprocolThe risk or severity of adverse effects can be increased when Olsalazine is combined with Masoprocol.
Meclofenamic acidMeclofenamic acid may increase the nephrotoxic activities of Olsalazine.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Meclofenamic acid.
Mefenamic acidMefenamic acid may increase the nephrotoxic activities of Olsalazine.
Mefenamic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Mefenamic acid.
MeloxicamMeloxicam may increase the nephrotoxic activities of Olsalazine.
MeloxicamThe risk or severity of adverse effects can be increased when Olsalazine is combined with Meloxicam.
MercaptopurineThe metabolism of Mercaptopurine can be decreased when combined with Olsalazine.
MesalazineMesalazine may increase the nephrotoxic activities of Olsalazine.
MetamizoleMetamizole may increase the nephrotoxic activities of Olsalazine.
MetamizoleThe risk or severity of adverse effects can be increased when Olsalazine is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Olsalazine.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olsalazine.
MetipranololOlsalazine may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Olsalazine.
MetoprololOlsalazine may decrease the antihypertensive activities of Metoprolol.
MetrizamideOlsalazine may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Olsalazine.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Olsalazine.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Olsalazine.
Mycophenolate mofetilMycophenolate mofetil may increase the nephrotoxic activities of Olsalazine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Mycophenolate mofetil.
Mycophenolic acidMycophenolic acid may increase the nephrotoxic activities of Olsalazine.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Mycophenolic acid.
NabumetoneNabumetone may increase the nephrotoxic activities of Olsalazine.
NabumetoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Nabumetone.
NadololOlsalazine may decrease the antihypertensive activities of Nadolol.
NadroparinOlsalazine may increase the anticoagulant activities of Nadroparin.
NaftifineNaftifine may increase the nephrotoxic activities of Olsalazine.
NaftifineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Naftifine.
NaproxenNaproxen may increase the nephrotoxic activities of Olsalazine.
NaproxenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Naproxen.
NCX 4016NCX 4016 may increase the nephrotoxic activities of Olsalazine.
NCX 4016The risk or severity of adverse effects can be increased when Olsalazine is combined with NCX 4016.
NeomycinOlsalazine may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacNepafenac may increase the nephrotoxic activities of Olsalazine.
NepafenacThe risk or severity of adverse effects can be increased when Olsalazine is combined with Nepafenac.
NetilmicinOlsalazine may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidNiflumic Acid may increase the nephrotoxic activities of Olsalazine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Niflumic Acid.
NimesulideNimesulide may increase the nephrotoxic activities of Olsalazine.
NimesulideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Olsalazine.
OlopatadineOlopatadine may increase the nephrotoxic activities of Olsalazine.
OlopatadineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Olopatadine.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Olsalazine.
OrgoteinOrgotein may increase the nephrotoxic activities of Olsalazine.
OrgoteinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Orgotein.
OtamixabanOlsalazine may increase the anticoagulant activities of Otamixaban.
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Olsalazine.
OxaprozinOxaprozin may increase the nephrotoxic activities of Olsalazine.
OxaprozinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Oxaprozin.
OxprenololOlsalazine may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneOxyphenbutazone may increase the nephrotoxic activities of Olsalazine.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Pamidronate.
ParecoxibParecoxib may increase the nephrotoxic activities of Olsalazine.
ParecoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Parecoxib.
ParnaparinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Parnaparin.
ParomomycinOlsalazine may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololOlsalazine may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateOlsalazine may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Olsalazine.
PhenindioneOlsalazine may increase the anticoagulant activities of Phenindione.
PhenprocoumonOlsalazine may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazonePhenylbutazone may increase the nephrotoxic activities of Olsalazine.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Phenylbutazone.
PimecrolimusPimecrolimus may increase the nephrotoxic activities of Olsalazine.
PimecrolimusThe risk or severity of adverse effects can be increased when Olsalazine is combined with Pimecrolimus.
PindololOlsalazine may decrease the antihypertensive activities of Pindolol.
PiretanideOlsalazine may decrease the diuretic activities of Piretanide.
PirfenidonePirfenidone may increase the nephrotoxic activities of Olsalazine.
PirfenidoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Pirfenidone.
PiroxicamPiroxicam may increase the nephrotoxic activities of Olsalazine.
PiroxicamThe risk or severity of adverse effects can be increased when Olsalazine is combined with Piroxicam.
PlicamycinOlsalazine may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Olsalazine.
PractololOlsalazine may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Olsalazine.
ProbenecidThe serum concentration of Olsalazine can be increased when it is combined with Probenecid.
PropacetamolPropacetamol may increase the nephrotoxic activities of Olsalazine.
PropacetamolThe risk or severity of adverse effects can be increased when Olsalazine is combined with Propacetamol.
PropranololOlsalazine may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Olsalazine.
Protein COlsalazine may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeOlsalazine may increase the anticoagulant activities of Protocatechualdehyde.
PTC299PTC299 may increase the nephrotoxic activities of Olsalazine.
PTC299The risk or severity of adverse effects can be increased when Olsalazine is combined with PTC299.
PuromycinOlsalazine may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Olsalazine.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Olsalazine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Olsalazine.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Olsalazine.
ResveratrolResveratrol may increase the nephrotoxic activities of Olsalazine.
ResveratrolThe risk or severity of adverse effects can be increased when Olsalazine is combined with Resveratrol.
ReviparinOlsalazine may increase the anticoagulant activities of Reviparin.
RibostamycinOlsalazine may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Risedronate.
RivaroxabanOlsalazine may increase the anticoagulant activities of Rivaroxaban.
RofecoxibRofecoxib may increase the nephrotoxic activities of Olsalazine.
RofecoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Rofecoxib.
SalicylamideSalicylamide may increase the nephrotoxic activities of Olsalazine.
SalicylamideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Salicylamide.
Salicylic acidSalicylic acid may increase the nephrotoxic activities of Olsalazine.
Salicylic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Salicylic acid.
SalsalateSalsalate may increase the nephrotoxic activities of Olsalazine.
SalsalateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Olsalazine.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Olsalazine.
SeratrodastSeratrodast may increase the nephrotoxic activities of Olsalazine.
SeratrodastThe risk or severity of adverse effects can be increased when Olsalazine is combined with Seratrodast.
SotalolOlsalazine may decrease the antihypertensive activities of Sotalol.
SpectinomycinOlsalazine may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Olsalazine.
SpironolactoneOlsalazine may decrease the antihypertensive activities of Spironolactone.
SRT501SRT501 may increase the nephrotoxic activities of Olsalazine.
SRT501The risk or severity of adverse effects can be increased when Olsalazine is combined with SRT501.
StreptomycinOlsalazine may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinOlsalazine may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazineSulfasalazine may increase the nephrotoxic activities of Olsalazine.
SulindacSulindac may increase the nephrotoxic activities of Olsalazine.
SulindacThe risk or severity of adverse effects can be increased when Olsalazine is combined with Sulindac.
SulodexideOlsalazine may increase the anticoagulant activities of Sulodexide.
SuprofenSuprofen may increase the nephrotoxic activities of Olsalazine.
SuprofenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Suprofen.
TacrolimusOlsalazine may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Olsalazine.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Olsalazine.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Olsalazine.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Olsalazine.
TenofovirThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tenofovir.
TenoxicamTenoxicam may increase the nephrotoxic activities of Olsalazine.
TenoxicamThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tenoxicam.
TepoxalinTepoxalin may increase the nephrotoxic activities of Olsalazine.
TepoxalinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tepoxalin.
TeriflunomideTeriflunomide may increase the nephrotoxic activities of Olsalazine.
TeriflunomideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Teriflunomide.
Tiaprofenic acidTiaprofenic acid may increase the nephrotoxic activities of Olsalazine.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tiaprofenic acid.
TiludronateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tiludronate.
TimololOlsalazine may decrease the antihypertensive activities of Timolol.
TinzaparinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tinzaparin.
TioguanineThe metabolism of Tioguanine can be decreased when combined with Olsalazine.
TobramycinOlsalazine may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidTolfenamic Acid may increase the nephrotoxic activities of Olsalazine.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tolfenamic Acid.
TolmetinTolmetin may increase the nephrotoxic activities of Olsalazine.
TolmetinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tolmetin.
TorasemideOlsalazine may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Olsalazine.
TranilastTranilast may increase the nephrotoxic activities of Olsalazine.
TranilastThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Olsalazine.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Olsalazine.
TriamtereneOlsalazine may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Olsalazine.
Trisalicylate-cholineTrisalicylate-choline may increase the nephrotoxic activities of Olsalazine.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Trisalicylate-choline.
ValdecoxibValdecoxib may increase the nephrotoxic activities of Olsalazine.
ValdecoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Valdecoxib.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Olsalazine.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Olsalazine.
WarfarinOlsalazine may increase the anticoagulant activities of Warfarin.
XimelagatranOlsalazine may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenZaltoprofen may increase the nephrotoxic activities of Olsalazine.
ZaltoprofenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Zaltoprofen.
ZileutonZileuton may increase the nephrotoxic activities of Olsalazine.
ZileutonThe risk or severity of adverse effects can be increased when Olsalazine is combined with Zileuton.
Zoledronic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Zoledronic acid.
ZomepiracZomepirac may increase the nephrotoxic activities of Olsalazine.
ZomepiracThe risk or severity of adverse effects can be increased when Olsalazine is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Thiopurine s-methyltransferase activity
Specific Function:
Catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine.
Gene Name:
TPMT
Uniprot ID:
P51580
Molecular Weight:
28180.09 Da
References
  1. Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L, Weinshilboum RM, Nierenberg DW: Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther. 1997 Oct;62(4):464-75. [PubMed:9357398 ]
  2. Lennard L: TPMT in the treatment of Crohn's disease with azathioprine. Gut. 2002 Aug;51(2):143-6. [PubMed:12117866 ]
  3. Lennard L: Clinical implications of thiopurine methyltransferase--optimization of drug dosage and potential drug interactions. Ther Drug Monit. 1998 Oct;20(5):527-31. [PubMed:9780130 ]
  4. Shipkova M, Niedmann PD, Armstrong VW, Oellerich M, Wieland E: Determination of thiopurine methyltransferase activity in isolated human erythrocytes does not reflect putative in vivo enzyme inhibition by sulfasalazine. Clin Chem. 2004 Feb;50(2):438-41. [PubMed:14752016 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Interferon-gamma receptor binding
Specific Function:
Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons.
Gene Name:
IFNG
Uniprot ID:
P01579
Molecular Weight:
19348.165 Da
References
  1. Egan LJ, Sandborn WJ: Inhibition of nuclear factor kappaB by sulfasalazine: a new target for inflammatory bowel disease therapy? Gastroenterology. 1998 Nov;115(5):1295-6. [PubMed:9797390 ]
  2. Ito R, Shin-Ya M, Kishida T, Urano A, Takada R, Sakagami J, Imanishi J, Kita M, Ueda Y, Iwakura Y, Kataoka K, Okanoue T, Mazda O: Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol. 2006 Nov;146(2):330-8. [PubMed:17034586 ]
Comments
comments powered by Disqus
Drug created on March 30, 2007 06:25 / Updated on August 17, 2016 12:23